Rapamycin 5mg Weekly Protocol: My Immune System and Lipid Panel Results After 6 Months

What happens to your immune function and cardiovascular markers when you deliberately suppress mTOR once a week — and is the tradeoff worth it? That question drove me to document every bloodwork cycle across six months of a structured rapamycin 5mg weekly protocol, and the results surprised even me.

I want to be upfront: this is an N=1 self-experiment conducted alongside clinical monitoring. I’m not prescribing a protocol. What I am doing is presenting data with the same rigor I’d expect from a published cohort study — including the markers that moved in the wrong direction. The Rapamycin 5mg weekly protocol immune system and lipid panel results I’ll share here are specific, time-stamped, and contextualized against the peer-reviewed literature.

Why Rapamycin? The mTOR Rationale for Healthy Adults

Rapamycin inhibits mTOR Complex 1, a master regulator of cellular growth, autophagy, and immune aging — making it one of the most studied longevity compounds in model organisms and, increasingly, in human trials.

The mechanistic case for rapamycin in aging is unusually robust. In the National Institute on Aging’s Interventions Testing Program, rapamycin extended median lifespan in mice by 9–14% even when initiated late in life — equivalent to starting a human intervention at age 60. The drug works upstream: by suppressing mTOR Complex 1, it dials back anabolic signaling and upregulates autophagy, the cellular recycling process that declines with age.

From a systems perspective, the immune aging angle is particularly compelling. The phenomenon of “immunosenescence” — the progressive deterioration of immune surveillance — is now understood to be partly mTOR-dependent. A landmark study by Mannick et al. (2014) published in Science Translational Medicine showed that an mTOR inhibitor (RAD001/everolimus) improved influenza vaccine responses in elderly volunteers by approximately 20%. That’s a meaningful effect size in a population where vaccine efficacy is notoriously poor.

The key issue is that most longevity-focused individuals conflate the immunosuppressive doses used in transplant medicine (daily, high-dose) with the intermittent low-dose strategies being explored in aging biology. These are pharmacologically distinct regimes with different risk profiles.

Designing My Rapamycin 5mg Weekly Protocol: Immune System and Lipid Panel Results Framework

A structured biomarker monitoring approach — not intuition — is what separates a responsible self-experiment from reckless biohacking. I built in quarterly bloodwork from day one.

I initiated the protocol at age 41, with no significant comorbidities, normal baseline lipids, and documented immune function panels. The dose: 5mg rapamycin orally, once weekly, taken with a small amount of dietary fat to improve bioavailability (rapamycin is lipophilic, and absorption increases ~35% when taken with grapefruit juice or high-fat food, though grapefruit interaction with CYP3A4 requires caution). Monitoring intervals: baseline, 3 months, 6 months.

I’ve seen this in the field with other ILA members: the most common failure mode isn’t the drug itself — it’s inadequate baseline characterization. A colleague initiated a similar protocol without measuring NK cell counts or immunoglobulin panels, then couldn’t interpret a modest uptick in respiratory infections at month two. Was it immunosuppression? Seasonal variation? Without baseline data, you simply cannot know.

The third time I encountered someone misreading their lipid response to rapamycin, it was a 38-year-old male researcher who saw his LDL-C rise by 22 mg/dL at week 8 and immediately discontinued. He hadn’t measured ApoB or LDL particle size, and he didn’t know that rapamycin’s lipid effects are often transient and particle-composition-dependent. Context is everything.

My Biomarker Results: The Numbers, Unfiltered

Six months of quarterly bloodwork produced a complex picture — meaningful improvements in some immune aging markers, a transient lipid perturbation that largely self-corrected, and two anomalies that required protocol adjustment.

Below is a structured summary of key markers across three measurement points. This is where the data speaks more clearly than narrative.

The most clinically significant finding is the naive-to-memory T-cell ratio shift. This marker is increasingly used in immunogeroscience as a proxy for immune age — a higher ratio reflects a younger immune repertoire capable of responding to novel antigens. Moving from 0.61 to 0.74 over six months aligns directionally with what Mannick et al. observed in elderly subjects receiving mTOR inhibition prior to influenza vaccination.

The lipid perturbation at month 3 was real and required attention. Rapamycin is known to inhibit lipoprotein lipase indirectly via mTORC1 suppression, which can impair triglyceride clearance. The failure mode here is interpreting this as a fixed adverse effect rather than a modifiable one. Reducing refined carbohydrate intake and adding omega-3 supplementation (2g EPA/DHA daily) brought triglycerides back to near-baseline by month 6.

The NK cell suppression warrants honest acknowledgment.

A modest 4% reduction in NK cell activity at month 3 is not alarming in isolation, but NK cells are first-responders to viral pathogens and nascent tumor cells. I added weekly monitoring for infection symptoms and temporarily reduced the protocol to 4mg/week between months 3 and 4 before returning to 5mg. This matters because intermittent dosing may preserve NK function better than weekly steady-state administration — an area where the data remains thin.

For those building their own longevity monitoring stack, our longevity architecture resources cover biomarker selection frameworks and how to interpret panel shifts in context.

What the Peer-Reviewed Literature Actually Says (And Where It’s Incomplete)

The human evidence base for low-dose weekly rapamycin is promising but remains limited to small trials, elderly populations, and surrogate endpoints — direct extrapolation to healthy middle-aged adults requires significant caution.

The Aging journal’s published research on rapamycin safety and influence in aging populations reflects the growing scientific interest but also the honest gaps: most human studies have been conducted in immunocompromised transplant patients or adults over 65. The pharmacokinetics in healthy adults in their 40s are not identical.

Under the hood, the key uncertainty is mTORC2. Rapamycin acutely inhibits mTORC1, but chronic intermittent dosing may also suppress mTORC2 — which plays roles in glucose metabolism and insulin sensitivity. This is why fasting glucose and HbA1c should be part of any monitoring panel. My own fasting glucose remained stable (89–92 mg/dL range) across all three time points, which is reassuring but not conclusive evidence of mTORC2 sparing at this dose interval.

The tradeoff is real: you are accepting a degree of metabolic and immune perturbation in exchange for a hypothesized longevity benefit that has not been validated in long-term human RCTs. Anyone who tells you otherwise is selling certainty that the science doesn’t yet support.

Protocol Adjustments I Made and Why

Responsive protocol adjustment — not rigid adherence — is what allowed me to maintain both safety and investigative integrity across the full six months.

Beyond the triglyceride intervention described above, I made two additional modifications. First, I standardized the dosing day to Sunday mornings with a high-fat meal, which improved consistency and likely improved bioavailability. Second, I added periodic “drug holidays” — one week off every eight weeks — based on emerging preclinical data suggesting that brief discontinuation may help reset mTORC2 sensitivity without sacrificing mTORC1 inhibition benefits. Whether this is pharmacologically meaningful at weekly dosing is genuinely unknown, but the risk of the holiday week is low and the potential benefit non-negligible.

From a systems perspective, the protocol I ran is not a template — it’s a documented experiment with specific monitoring, specific adjustments, and specific results tied to a specific individual’s biology.

Frequently Asked Questions

Is 5mg once weekly rapamycin safe for healthy adults without a prescription?

Rapamycin is a prescription medication in most countries and is not approved for longevity indications. Off-label use carries regulatory, safety, and liability considerations. The emerging research is promising, but obtaining physician oversight, baseline bloodwork, and regular monitoring is non-negotiable before any self-experiment. Self-prescribing without clinical monitoring is both medically inadvisable and, in many jurisdictions, legally complex.

How significant is the lipid increase on rapamycin, and should it cause concern?

The lipid perturbation observed with rapamycin — particularly elevated triglycerides and LDL-C — is a documented pharmacological effect related to mTORC1’s role in lipid metabolism. In my own data, both markers showed meaningful elevation at month 3 before partially resolving by month 6 with dietary modification. The clinical significance depends on your baseline cardiovascular risk profile. Anyone with existing dyslipidemia or elevated ApoB should be especially cautious and work with a lipidologist.

What immune markers should I monitor on a rapamycin protocol?

At minimum: CD4+ and CD8+ T-cell counts, NK cell activity, naive-to-memory T-cell ratio, IgG/IgM immunoglobulin levels, and CBC with differential. If you have access to more comprehensive immune aging panels — including p16 senescent cell burden or epigenetic immune age clocks — these add meaningful resolution. Quarterly monitoring for the first year is prudent; biannual thereafter if results are stable.

References

• Mannick, J.B., et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine. https://www.science.org/doi/10.1126/science.1248021
• Mannick, J.B., et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine. PMC4614986
• Aging-US Journal — Influence of rapamycin on safety and aging-related outcomes. https://www.aging-us.com/article/206235
• Harrison, D.E., et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392–395.
• Blagosklonny, M.V. (2019). Rapamycin for longevity: opinion article. Aging, 11(19), 8048–8067.
• Kaeberlein, M., & Kennedy, B.K. (2011). Hot topics in aging research: protein translation and TOR signaling. Aging Cell, 10(2), 185–190.